Monopar Therapeutics
Clinical-stage biotech developing radiopharmaceuticals for oncology and rare diseases.
MNPR | US
Overview
Corporate Details
- ISIN(s):
- US61023L2079
- LEI:
- Country:
- United States of America
- Address:
- 1000 SKOKIE BLVD SUITE 350, 60091 WILMETTE
- Website:
- https://www.monopartx.com/
Description
Monopar Therapeutics is a clinical-stage biotechnology company developing novel radiopharmaceuticals for oncology and a treatment for Wilson Disease, a rare genetic disorder. Its oncology pipeline focuses on radiopharmaceutical candidates targeting the urokinase plasminogen activator receptor (uPAR) in advanced solid tumors. These include MNPR-101-Zr for imaging, the clinical-stage therapeutic MNPR-101-Lu, and the late-preclinical stage therapeutic MNPR-101-Ac. For rare diseases, the company is advancing ALXN1840, a late-stage investigational drug for the treatment of Wilson Disease. Monopar builds its pipeline through in-house development and by in-licensing late-stage clinical assets.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Monopar Therapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Monopar Therapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Monopar Therapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
